As an example, SLC29A1 and DCK silencing via DNA methylation in some gemcitabine-resistant pancreatic cancer patients could be targeted with a pharmaco-epigenetic approach using DNMT inhibitors alongside gemcitabine [30]. The gene discussed is SLC29A1; the disease is pancreatic neoplasm.